ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,887 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselTargImmune Therapeutics AG
TargImmune Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of TargImmune Therapeutics AG is the development and research of oncological compounds and the development of a modular, synthetic, targeted platform technology for nucleic acid therapy. In particular, the company focuses on the development of targeted apoptosis and immunomodulators (TAIMs) that use synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly to the target. The goal is to selectively destroy cancer cells by mimicking natural processes.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

TargImmune Therapeutics AG

✓ Offered2
Targeted nucleic acid delivery platform (TAIMs)
Targeted nucleic acid delivery platform using synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly on target; developed as targeted apoptosis and immune modulators for cancer and other therapy areas.
Oncology agents (TAR001, TAR002, TAR003)
Oncology drug programs based on the TAIM platform, initially focused on three receptor targets; lead compound TAR001 delivers dsRNA to targeted cancer cells and is being developed for multiple solid tumours.
Trust & reputation

ranQ Trust Score of TargImmune Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

TargImmune Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
TargImmune Therapeutics AG scores 79.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.86.512%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
TargImmune Therapeutics AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
TargImmune Therapeutics AG scores 23.8 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.34.34%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.13.34%
Qualifications+0.00

TargImmune Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

March 20, 2025Media
TargImmune Therapeutics gets acquired
startupticker.ch

Knowledge

No knowledge articles yet

Once TargImmune Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

TargImmune Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank TargImmune Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of TargImmune Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

St. Alban-Anlage 70
4052 Basel

At a glance

Legal form
Corporation
UID
CHE-349.430.797
Founded
2016 · 10 years
Last commercial register change
August 27, 2026
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    MS
    Moderna Switzerland GmbH
    Basel
    CT
    CORETAG Therapeutics AG
    Basel
    LM
    Laevoroc Medical AG
    Basel
    AG
    AlphaMeld GmbH
    Basel
    3B
    3T Biosciences Europe GmbH
    Basel
    NA
    NBE-Therapeutics AG
    Basel
    GA
    Galvita AG
    Basel
    FA
    FimmCyte AG
    Basel